Search Results - "Insa Mollá, Amelia"

Crizotinib and renal insufficiency: A case report and review of the literature by Martín Martorell, Paloma, Huerta Alvaro, Marisol, Solís Salguero, Miguel A, Insa Molla, Amelia

“…Abstract A 69 year old man with idiopathic chronic kidney disease was diagnosed with relapsing EGFR negative, ALK positive lung adenocarcinoma, and treated…”
Get full text

Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study by Gambardella, Valentina, Lombardi, Pasquale, Carbonell-Asins, Juan Antonio, Tarazona, Noelia, Cejalvo, Juan Miguel, González-Barrallo, Inés, Martín-Arana, Jorge, Tébar-Martínez, Roberto, Viala, Alba, Bruixola, Gema, Hernando, Cristina, Blasco, Inma, Papaccio, Federica, Martínez-Ciarpaglini, Carolina, Alfaro-Cervelló, Clara, Seda-García, Enrique, Blesa, Sebastián, Chirivella, Isabel, Castillo, Josefa, Montón-Bueno, José Vicente, Roselló, Susana, Huerta, Marisol, Pérez-Fidalgo, Alejandro, Martín-Martorell, Paloma, Insa-Mollá, Amelia, Fleitas, Tania, Rentero-Garrido, Pilar, Zúñiga-Trejos, Sheila, Cervantes, Andrés, Roda, Desamparados

“…Introduction Molecular-matched therapies have revolutionized cancer treatment. We evaluated the improvement in clinical outcomes of applying an in-house…”
Get full text

Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP by Ospina, Aylen Vanessa, Bolufer Nadal, Sergio, Campo-Cañaveral de la Cruz, José Luis, González Larriba, Jose Luis, Macía Vidueira, Ivan, Massutí Sureda, Bartomeu, Nadal, Ernest, Trancho, Florentino Hernando, Álvarez Kindelán, Antonio, Del Barco Morillo, Edel, Bernabé Caro, Reyes, Bosch Barrera, Joaquim, Calvo de Juan, Virginia, Casal Rubio, Joaquin, de Castro, Javier, Cilleruelo Ramos, Ángel, Cobo Dols, Manuel, Dómine Gómez, Manuel, Figueroa Almánzar, Santiago, Garcia Campelo, Rosario, Insa Mollá, Amelia, Jarabo Sarceda, José Ramón, Jiménez Maestre, Unai, López Castro, Rafael, Majem, Margarita, Martinez-Marti, Alex, Martínez Téllez, Elisabeth, Sánchez Lorente, David, Provencio, Mariano

“…Introduction Recent advances in the treatment of locally advanced NSCLC have led to changes in the standard of care for this disease. For the selection of the…”
Get full text

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial by Paz-Ares, Luis, Dvorkin, Mikhail, Chen, Yuanbin, Reinmuth, Niels, Hotta, Katsuyuki, Hochmair, Maximilian J, Özgüroğlu, Mustafa, Ji, Jun Ho, Bondarenko, Igor, Byrne, Natalie, Shire, Norah, Goldman, Jonathan W, Batagelj, Emilio, Casarini, Ignacio, Pastor, Anea Viviana, Hartl, Sylvia, Hochmair, Maximilian J, Lamprecht, Bernd, Dos Reis, Peo, Serodio da Rocha Baldotto, Clarissa, Venkova, Violetka, Bi, Minghong, Chen, Zhendong, Han, Zhigang, Hu, Yi, Li, Wei, Ma, Shenglin, Nan, Kejun, Shu, Yongqian, Wang, Kai, Yang, Nong, Zhang, Wei, Zhao, Jun, Zhao, Yanqiu, Zhou, Caicun, Zhou, Xiangdong, Skrickova, Jana, Hilgers, Werner, Moro-Sibilot, Denis, Bischoff, Helge, Lang, Susanne, Fülöp, Anea, Horváth, Zsolt, Laczó, Ibolya, Losonczy, György, Pápai Székely, Zsolt, Telekes, Anás, Bar, Jair, Gottfried, Maya, Heching, Norman Isaac, Bettini, Anna Cecilia, Minelli, Mauro, Roila, Fausto, Verderame, Francesco, Atagi, Shinji, Goto, Hisatsugu, Goto, Koichi, Hara, Yu, Hida, Toyoaki, Hotta, Katsuyuki, Kuyama, Shoichi, Morise, Masahiro, Nakahara, Yasuharu, Okamoto, Isamu, Shinoda, Masahiro, Umemura, Shigeki, Heniks, Lizza, Ungureanu, Anei, Luft, Alexander, Sakaeva, Dina, Smolin, Alexey, Statsenko, Galina, Vasilyev, Alexander, Vladimirova, Lyubov, Chovanec, Jozef, Urda, Michal, Ji, Jun Ho, Lee, Kyung Hee, Isla Casado, Dolores, Ponce Aix, Santiago, Hsia, Te-Chun, Wu, Shang-Yin, Çiçin, Irfan, Göksel, Tuncay, Özgüroğlu, Mustafa, Adamchuk, Hryhoriy, Bondarenko, Igor, Kryzhanivska, Anna, Shevnia, Serhii, Trukhin, Dmytro, Ursol, Grygorii, Voitko, Oleksandr, Vynnychenko, Ihor, Chen, Yuanbin, Chua, Winston, Dakhil, Shaker, Goldman, Jonathan W, Lakhanpal, Shailena, Powell, Steven, Stilwill, Joseph

“…Most patients with small-cell lung cancer (SCLC) have extensive-stage disease at presentation, and prognosis remains poor. Recently, immunotherapy has…”
Get full text

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial by Chen, Yuanbin, Reinmuth, Niels, Hotta, Katsuyuki, Özgüroğlu, Mustafa, Ji, Jun Ho, Garassino, Marina Chiara, Poltoratskiy, Artem, Ponce, Santiago, Bondarenko, Igor, Conev, Nikolay V, Armstrong, Jon, Byrne, Natalie, Jiang, Haiyi, Paz-Ares, Luis, Voitko, Nataliia, Poltoratskiy, Artem, Bondarenko, Igor, Chen, Yuanbin, Özgüroglu, Mustafa, Conev, Nikolay, Burghuber, Otto, Moiseenko, Vladimir, Reinmuth, Niels, Ursol, Grygorii, Pajkos, Gábor, Verderame, Francesco, Smolin, Alexey, Göksel, Tuncay, Dakhil, Shaker, Lee, Jong-Seok, Garcia Campelo, Maria Rosario, Alacacioglu, Ahmet, Casarini, Ignacio, Ilieva, Rumyana, Somfay, Attila, Roila, Fausto, Urda, Michal, Majem Tarruella, Margarita, Bettini, Anna Cecilia, Okamoto, Isamu, Mandziuk, Slawomir, Domine Gomez, Manuel, Wu, Shang-Yin, Knoble, Jeanna, Venkova, Violetka, Laack, Eckart, Bischoff, Helge, Fülöp, Andrea, Telekes, András, Kanda, Shintaro, Nakahara, Yasuharu, Lin, Sheng-Hao, Schaefer, Eric, Nikolinakos, Petros, Schneider, Jeffrey, Kultan, Juraj, Kolek, Vitezslav, Lee, Kyung Hee, Goloborodko, Olexandr, Kolesnik, Oleksii, Ostapenko, Yuriy, Stilwill, Joseph, De Marchi, Pedro Rafael Martins, Krasteva, Rositsa, Koubkova, Leona, Grohe, Christian, Heching, Norman Isaac, Harada, Daijiro, Nogami, Naoyuki, Nokihara, Hiroshi, Goto, Hisatsugu, Staal van den Brekel, Agnes, Ganea, Doina, Popova, Ekaterina, Sakaeva, Dina, Stresko, Marian, Demo, Pavol, Hsia, Te-Chun, Lee, Kang-Yun, Zarba, Juan Jose, Pastor, Andrea Viviana, Zukin, Mauro, Calabrich, Aknar, Dudov, Asen, Lang, Susanne, Kanazawa, Kenya, Hiltermann, Jeroen, Shparyk, Yaroslav, Kryzhanivska, Anna, Jamil, Rodney, Williamson, Michael, Han, Zhigang, Wang, Mengzhao, Li, Wei, Feng, Jifeng, Zhou, Xiangdong, Hu, Yi, Nan, Kejun, Zhang, Wei, Lin, Zhong

“…First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum–etoposide) showed a significant improvement in overall survival versus…”
Get full text

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial by Wu, Yi-Long, Cheng, Ying, Zhou, Jianying, Lu, Shun, Zhang, Yiping, Zhao, Jun, Kim, Dong-Wan, Soo, Ross Andrew, Kim, Sang-We, Pan, Hongming, Chen, Yuh-Min, Chian, Chih-Feng, Liu, Xiaoqing, Tan, Daniel Shao Weng, Bruns, Rolf, Straub, Josef, Johne, Andreas, Scheele, Jürgen, Park, Keunchil, Yang, James Chih-Hsin, Liu, Zhe, Chen, Xi, Wang, Mengzhao, Yu, Shiying, Zhang, Helong, Fang, Jian, Li, Wei, Yang, Chih-Hsin, Chang, Gee-Chen, Hsia, Te-Chun, Yang, Cheng-Ta, Wang, Chin-Chou, Cho, Byoung Chul, Lee, Ki Hyeong, Kim, Young-Chul, An, Ho Jung, Woo, In Sook, Cho, Jae Yong, Shin, Sang Won, Lee, Jong-Seok, Kim, Joo-Hang, Yoo, Seung Soo, Kato, Terufumi, Shinagawa, Naofumi, Tan, Shao Weng Daniel, Ngo, Lynette Si-Mien, Ratnavelu, Kananathan, Ahmad, Azura Rozila, Liam, Chong Kin, de Marinis, Filippo, Tassone, Pierfrancesco, Molla, Amelia Insa, Calles Blanco, Antonio, Lazaro Quintela, Martin Emilio, Felip Font, Enriqueta, Dingemans, Anne-Marie, Bui, Lynne

“…BACKGROUNDWe evaluated the efficacy and safety of tepotinib, a potent and highly selective oral MET inhibitor, plus gefitinib in patients with epidermal growth…”
Get full text

Prognostic factors of localized malignant melanoma: study of 639 patients by Nagore Enguídanos, Eduardo, Oliver Martínez, Vicente, Botella Estrada, Rafael, Insa Mollá, Amelia, Fortea Baixauli, José Miguel

“…Several clinical and histological prognostic factors have been identified in localized melanoma. However, further studies with better defined and more…”
Get more information

Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint inhibitor, as monotherapy in patients (pts) with advanced renal cell carcinoma (RCC): Preliminary results from an FTIH trial by Albiges, Laurence, Medina Rodriguez, Laura, Kim, Sang-We, Im, Seock-Ah, Carcereny, Enric, Rha, Sun Young, Tran, Ben, Oliveira, Julio, Maroto-Rey, Pablo, Su, Wu-Chou, Voskoboynik, Mark, Rodriguez-Vida, Alejo, Costa, Luis, Ascierto, Paolo Antonio, Insa Molla, Maria Amelia, Wang, Yi, Gainer, Shelby D., Subramaniam, Deepa S, Voss, Martin H

“…107 Background: MEDI5752 is a monovalent bispecific antibody targeting PD-1 and CTLA-4. A phase I, open-label study (NCT03530397) of MEDI5752 monotherapy…”
Get full text